Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07221344
PHASE1/PHASE2

Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

Sponsor: Arrowhead Pharmaceuticals

View on ClinicalTrials.gov

Summary

Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.

Official title: A Phase 1/2a Placebo-Controlled Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

112

Start Date

2025-11-18

Completion Date

2027-06

Last Updated

2025-12-11

Healthy Volunteers

Yes

Interventions

DRUG

ARO-MAPT-SC

• single or multiple doses of ARO-MAPT-SC by subcutaneous (SC) injection

DRUG

Placebo

• calculated volume to match active treatment by SC administration

Locations (1)

Research Site 1

Grafton, Auckland, New Zealand